Individuals who are infected with Trypanosoma cruzi develop chronic Chagas cardiomyopathy (CCC), which is a complication involving a series of immune pathogenetic mechanisms, although an association between immune and metabolic alterations was more recently proposed. Accordingly, we investigated the immuno-metabolic response in chagasic patients and their possible influence on CCC pathogenesis. To this end, T. cruzi-seropositive (asymptomatic or with CCC) and sero-negative individuals were studied. Serum tumour necrosis factor (TNF)-α, interleukin (IL)-6, adipocytokines and the expression of their receptors in peripheral blood mononuclear cell (PBMC) were evaluated, together with other factors influencing the immune response. CCC patients showed major metabolic and hormonal abnormalities, in parallel with increased IL-6 and leptin serum levels. TNF-α receptor s, leptin and adiponectin receptors (ObR and Adipo-Rs respectively), as well as PPAR-γ expression in PBMCs from CCC patients were compatible with a counteracting response leading to an unfavourable immune-metabolic profile. These results suggest that persistently increased levels of immune-metabolic pro-inflammatory mediators along with the adverse endocrine anti-inflammatory response of CCC individuals, may contribute to the underlying mechanisms dealing with myocardial tissue damage.

Journal Section:
Editor's choice
Keywords:
Chagas disease, Immuno-metabolism, Cortisol, Tumor necrosis factor-α, Interleukin-6, Adipocytokines, Tumor necrosis factor-α receptor type-1, ObR, Adiponectin receptor type-1
1.
Pinto Dias JC: Human chagas disease and migration in the context of globalization: Some particular aspects. J Trop Med 2013; 2013: 789758.
2.
Longo DL, Bern C: Chagas’ disease. N Engl J Med 2015; 373: 456–466.
3.
Coura JR: The main sceneries of Chagas disease transmission. The vectors, blood and oral transmissions – a comprehensive review. Mem Inst Oswaldo Cruz 2015; 110: 277–282.
4.
Rassi A, Rassi A, Marin-Neto JA: Chagas disease. Lancet 2010; 375: 1388–1402.
5.
WHO Expert Committee: Control of Chagas Disease: Second report of the WHO expert committee. World Heal Organ – Tech Rep Ser 2002;1–99.
6.
Johnson RW: Immune and endocrine regulation of food intake in sick animals. Domest Anim Endocrinol 1998; 15: 309–319.
7.
Rondinone CM: Adipocyte-derived hormones, cytokines, and mediators. Endocrine 2006; 29: 81–90.
8.
Karbowska J, Kochan Z: Fat-reducing effects of dehydroepiandrosterone involve upregulation of ATGL and HSL expression, and stimulation of lipolysis in adipose tissue. Steroids 2012; 77: 1359–1365.
9.
Karbowska J, Kochan Z: Effects of DHEA on metabolic and endocrine functions of adipose tissue. Horm Mol Biol Clin Investig 2013; 14: 65–74.
10.
Dillon JS: Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: their role in inflammatory, allergic and immunological disorders. Curr Drug Targets Inflamm Allergy 2005; 4: 377–385.
11.
Straub RH, Paimela L, Peltomaa R, Schölmerich J, Leirisalo-Repo M: Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis Rheum 2002; 46: 654–662.
12.
Perez AR, Silva-Barbosa SD, Berbert LR, Revelli S, Beloscar J, Savino W, et al: Immunoneuroendocrine alterations in patients with progressive forms of chronic Chagas disease. J Neuroimmunol 2011; 235: 84–90.
13.
dos Santos VM, da Cunha SF, Teixeira V de P, Monteiro JP, dos Santos JA, dos Santos TA, et al: Frequency of diabetes mellitus and hyperglycemia in chagasic and non-chagasic women. Rev Soc Bras Med Trop 1999; 32: 489–496.
14.
Cabalén ME, Cabral MF, Sanmarco LM, Andrada MC, Onofrio LI, Ponce NE, et al: Chronic Trypanosoma cruzi infection potentiates adipose tissue macrophage polarization toward an anti-inflammatory M2 phenotype and contributes to diabetes progression in a diet-induced obesity mode. Oncotarget 2016; 7: 13400–13415.
15.
Nagajyothi F, Desruisseaux MS, MacHado FS, Upadhya R, Zhao D, Schwartz GJ, et al: Response of adipose tissue to early infection with trypanosoma cruzi (Brazil Strain). J Infect Dis 2012; 205: 830–840.
16.
Nagajyothi F, Desruisseaux MS, Thiruvur N, Weiss LM, Braunstein VL, Albanese C, et al: Trypanosoma cruzi Infection of cultured adipocytes results in an inflammatory phenotype. Obesity 2008; 16: 1992–1997.
17.
Cabalén ME, Cabral MF, Sanmarco LM, Andrada MC, Onofrio LI, Ponce NE, et al: Chronic Trypanosoma cruzi infection potentiates adipose tissue macrophage polarization toward an anti-inflammatory M2 phenotype and contributes to diabetes progression in a diet-induced obesity model. Oncotarget 2016; 7: 13400–13415.
18.
Combs TP, Nagajyothi, Mukherjee S, De Almeida CJ, Jelicks LA, Schubert W, et al: The adipocyte as an important target cell for Trypanosoma cruzi infection. J Biol Chem 2005; 280: 24085–24094.
19.
Tanowitz HB, Jelicks LA, Machado FS, Esper L, Qi X, Desruisseaux MS, et al: Adipose tissue, diabetes and chagas disease. Adv Parasitol 2011; 76: 235–250.
20.
Ferreira AVM, Segatto M, Menezes Z, Macedo AM, Gelape C, de Oliveira Andrade L, et al: Evidence for Trypanosoma cruzi in adipose tissue in human chronic Chagas disease. Microbes Infect 2011; 13: 1002–1005.
21.
Barbosa-Ferreira JM, Mady C, Ianni BM, Lopes HF, Ramires FJA, Salemi VMC, et al: Dysregulation of autonomic nervous system in chagas’ heart disease is associated with altered adipocytokines levels. PLoS One 2015; 10:e0131447.
22.
Garzon SA, Lorga AM, Nicolau JC: Electrocardiography in Chagas’ heart disease. Sao Paulo Med J 1995; 113: 802–813.
23.
Alberti KGMM, Zimmet P, Shaw J: Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469–480.
24.
Alberti KGMM, Zimmet P, Shaw J: The metabolic syndrome – a new worldwide definition. Lancet 2005; 366: 1059–1062.
25.
Törüner F, Akbay E, Cakir N, Sancak B, Elbeg S, Taneri F, et al: Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese rats. Horm Metab Res 2004; 36: 226–230.
26.
Jiang C, Ting AT, Seed B: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82–86.
27.
Yang XY, Wang LH, Chen T, Hodge DR, Resau JH, DaSilva L, et al: Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem 2000; 275: 4541–4544.
28.
Geraix J, Ardisson LP, Marcondes-Machado J, Pereira PC: Clinical and nutritional profile of individuals with Chagas disease. Braz J Infect Dis 2007; 11: 411–414.
29.
Compagnucci AB, Dávila A, Beloscar J, Pezzotto SM, Dávila H: Ingesta alimentaria y estado nutricional de pacientes con enfermedad de Chagas. Arch Latinoam Nutr 2016; 66: 185–194.
30.
Martí A, Marcos A, Martínez JA: Obesity and immune function relationships. Obes Rev 2001; 2: 131–140.
31.
Milner JJ, Beck MA: The impact of obesity on the immune response to infection. Proc Nutr Soc 2012; 71: 298–306.
32.
Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, et al: Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009; 15: 930–939.
33.
Lumeng CN, Delproposto JB, Westcott DJ, Saltiel AR: Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes 2008; 57: 3239–3246.
34.
Strissel KJ, DeFuria J, Shaul ME, Bennett G, Greenberg AS, Obin MS: T-cell recruitment and Th1 polarization in adipose tissue during diet-induced obesity in C57BL/6 mice. Obesity (Silver Spring) 2010; 18: 1918–1925.
35.
Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796–1808.
36.
Skurk T, Alberti-Huber C, Herder C, Hauner H: Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007; 92: 1023–1033.
37.
Moriyama Y, Yasue H, Yoshimura M, Mizuno Y, Nishiyama K, Tsunoda R, et al: The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. J Clin Endocrinol Metab 2000; 85: 1834–1840.
38.
Santos CD, Toldo MP, Santello FH, Filipin Mdel V, Brazao V, do Prado Junior JC: Dehydroepiandrosterone increases resistance to experimental infection by Trypanosoma cruzi. Vet Parasitol 2008; 153: 238–243.
39.
Roggero E, Pérez AR, Tamae-Kakazu M, Piazzon I, Nepomnaschy I, Basedovsky HO, et al: Edogenous glucocorticoids cause thymus atrophy but are protective during acute Trypanosoma cruzi infection. J Endocrinol 2006; 190: 495–503.
40.
Myers MG, Leibel RL, Seeley RJ, Schwartz MW: Obesity and leptin resistance: Distinguishing cause from effect. Trends Endocrinol Metab 2010; 21: 643–651.
41.
Ouchi N, Shibata R, Walsh K: Cardioprotection by adiponectin. Trends Cardiovasc Med 2006; 16: 141–146.
42.
Mahajan R, Lau DH, Sanders P: Impact of obesity on cardiac metabolism, fibrosis, and function. Trends Cardiovasc Med 2015; 25: 119–126.
43.
Tanowitz HB, Amole B, Hewlett D, Wittner M: Trypanosoma cruzi infection in diabetic mice. Trans R Soc Trop Med Hyg 1988; 82: 90–93.
44.
Fernandes F, Dantas S, Ianni BM, Ramires FJ a, Buck P, Salemi VMC, et al: Leptin levels in different forms of Chagas’ disease. Braz J Med Biol Res 2007; 40: 1631–1636.
45.
Karmazyn M, Rajapurohitam V: Leptin as a cardiac pro-hypertrophic factor and its potential role in the development of heart failure. Curr Pharm Des 2014; 20: 646–651.
46.
Schulze PC, Kratzsch J, Linke A, Schoene N, Adams V, Gielen S, et al: Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur J Heart Fail 2003; 5: 33–40.
47.
Pereira Barretto AC, Mady C, Arteaga-Fernandez E, Stolf N, Lopes EA, Higuchi ML, et al: Right ventricular endomyocardial biopsy in chronic Chagas’ disease. Am Hear J 1986; 111: 307–312.
48.
Bornstein SR, Uhlmann K, Haidan A, Ehrhart-Bornstein M, Scherbaum WA: Evidence for a novel peripheral action of leptin as a metabolic signal to the adrenal gland: leptin inhibits cortisol release directly. Diabetes 1997; 46: 1235–1238.
49.
Shen Y, Charlesworth JA, Kelly JJ, Loi KW, Peake PW: Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease. Nephrol Dial Transplant 2007; 22: 171–178.
50.
Tan W, Wang F, Zhang M, Guo D, Zhang Q, He S: High adiponectin and adiponectin receptor 1 expression in synovial fluids and synovial tissues of patients with rheumatoid arthritis. Semin Arthritis Rheum 2009; 38: 420–427.
51.
Peschon JJ, Torrance DS, Stocking KL, Glaccum MB, Otten C, Willis CR, et al: TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998; 160: 943–952.
52.
Minigo G, Woodberry T, Piera KA, Salwati E, Tjitra E, Kenangalem E, et al: Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS Pathog 2009; 5:e1000402.
53.
Leininger MT, Portocarrero CP, Houseknecht KL: Peroxisome proliferator-activated receptor gamma1 expression in porcine white blood cells: dynamic regulation with acute endotoxemia. Biochem Biophys Res Commun 1999; 263: 749–753.
54.
Soller M, Tautenhahn A, Brüne B, Zacharowski K, John S, Link H, et al: Peroxisome proliferator-activated receptor gamma contributes to T lymphocyte apoptosis during sepsis. J Leukoc Biol 2006; 79: 235–243.
55.
Penas FN, Carta D, Dmytrenko G, Mirkin GA, Modenutti CP, Cevey ÁC, et al: Treatment with a new peroxisome proliferator-activated receptor gamma agonist, pyridinecarboxylic acid derivative, increases angiogenesis and reduces inflammatory mediators in the heart of Trypanosoma cruzi-infected mice. Front Immunol 2017; 8: 1738.
56.
Stefanou N, Satra M, Papanikolaou V, Kalala F, Gatselis N, Germenis A, et al: Leptin receptor isoforms mRNA expression in peripheral blood mononuclear cells from patients with chronic viral hepatitis. Exp Biol Med (Maywood) 2006; 231: 1653–1663.
© 2018 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.